Immutep (NASDAQ:IMMP) Stock, Quote.Headers.trade-ideas

Immutep

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

biotech shutter

Biotech

News

Health Care

Movers

Trading Ideas

General

IMMP

Immutep&#39;s INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy.

Immutep&#39;s Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Screenshot 2024-09-16 at 5.51.32 PM

Earnings

Equities

Eurozone

Commodities

Markets

BBLG

DRMA

NCNA

NWTN

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September

movers image

Pre-Market Outlook

EZPW

GPRK

IART

IOVA

NAMS

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Immutep Limited - American Depositary Shares

Immutep Ltd

Immutep: Navigating The Bumps In The Road

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GlaxoSmithKline (GB:GSK – Research Report), Gritstone Oncology (G...

Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Gritstone Oncology (GRTS) and Immutep (IMMP)

Immutep stock jumps 11% on positive data for eftilagimod alpha

Immutep (IMMP) has released an update. Immutep Limited has announced promising results from its Phase II trial of eftilagimod alpha, combined with ...

Immutep Reports Promising Phase II Sarcoma Trial Results

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Immutep (IMMP) announces the initiation of the pivotal TACTI-004 Phase III clinical trial for the treatment of first-line metastatic non-small cell...

Immutep announces initiation of TACTI-004 Phase III trial

Immutep (IMMP) announces positive clinical results from Cohort B of the TACTI-003 Phase IIb trial. This study evaluates eftilagimod alpha in combin...

Immutep announces results from Cohort B of TACTI-003 trial

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report), retaining the price target of $12.00. Jason McCa...

Immutep's Eftilagimod Alpha Shows Promising Results in Head and Neck Cancer Study, Justifying Buy Rating

Immutep (IMMP) announces new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ligand ...

Immutep, Monash University announce publication on human LAG-3

Immutep (IMMP) announces favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. T...

Immutep announces initial safety data from Phase I study on IMP761

GRTS

PRRUF

Press Releases

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep Quarterly Activities Report Q1 FY25

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Absci

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

aTyr Pharma

Benitec Biopharma

Cidara Therapeutics

Chimerix

Cardiff Oncology

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

ITeos Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Neurogene

Precigen

AVITA Medical

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Rezolute

Sage Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tango Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Valneva

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharma

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

XOMA Royalty

Y-mAbs Therapeutics

Baird

Capital One

Maxim Group

Comments

Immutep

Immutep (IMMP) Forecast

Immutep (NASDAQ:IMMP) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga